NEW YORK, Oct. 5, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed's management team will participate in the Cantor Fitzgerald Neurology & Psychiatry Conference, taking place at the Ritz Carlton, San Francisco, CA from October 6-7, 2022.
Cantor Fitzgerald Neurology & Psychiatry Conference
Format: Panel presentation and one-on-one investor meetings
Panel Title: "Tripping our way to a new treatment paradigm for psychiatric disorders: intermittent therapy vs chronic treatment"
Panel Date: Thursday, October 6, 2022
Panel Time: 12:10 p.m. PDT
Location: Ritz Carlton, San Francisco, CA
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: email@example.com
For Investors: firstname.lastname@example.org
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-participate-in-the-cantor-fitzgerald-neurology--psychiatry-conference-301641526.html
SOURCE Mind Medicine (MindMed) Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2022/05/c2048.html
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDAR.com for important risk disclosures. It’s your money and your responsibility.